Navigation Links
Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Date:11/21/2007

re treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Phase III Trial Finds Pharmaxis Bronchitol Effective
9. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
10. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... DIEGO, California, USA (PRWEB) August 28, 2014 ... the Department of Physics and Optical Science and Director ... the University of North Carolina at Charlotte, and co-founder ... been elected to serve as the 2015 Vice President ... , SPIE 2014 President Philip Stahl announced recent election ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
(Date:8/28/2014)... YORK , Aug. 28, ... that a new market research ... catalogue: Whole Exome ... Kits (Library Preparation, Target Enrichment), ... (Sequencing by Synthesis), by Application ...
(Date:8/28/2014)... SunTrust Robinson Humphrey (STRH) today announced the ... research team in biotechnology and oilfield services.  ... demonstrates our commitment to providing our valued institutional ... decision making," said Biff Woodruff , Head ... significant investments in differentiated content at a time ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... (NYSE: CRY ),a biomaterials, medical device and tissue ... will be released on,Thursday, July 31, 2008. The Company ... a.m. Eastern Time, July 31, 2008, to discuss the,results, ... Steven G.,Anderson, president and CEO of CryoLife, Inc., ...
... management system at its Gardner, Mass., facility, focusing on continuous process ... ... July 15, 2008 -- New England Peptide, LLC (NEP), is developing ... on continuous process improvement and customer satisfaction., , ,The program is ...
... AMSTERDAM, The Netherlands, July 15 Amsterdam,Molecular Therapeutics ... human gene,therapy, today announced the start of a ... Tennessee, USA, on the development,of a gene therapy ... will,receive the exclusive commercial rights to the final ...
Cached Biology Technology:CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration 2New England Peptide Implements Quality Management System, Prepares for ISO 9001: 2008 Registration 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 2AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 4
(Date:8/31/2014)... French . ... the prestigious Nature Neuroscience journal by, Sylvain Williams, ... Douglas Mental Health University Institute and McGill University, opens the ... mechanisms controlling memory as well of the role of an ... subiculum. , In 2009, they developed a unique approach ...
(Date:8/29/2014)... University of Texas Medical Branch at Galveston has gone on ... completely protect monkeys against a lethal dose of Ebola virus ... the disease is severe. , Thomas Geisbert, professor of microbiology ... discussing advances in Ebola treatment research. The filoviruses known as ... of pathogens, with fatality rates of up to 90 percent. ...
(Date:8/29/2014)... news release is available in German . ... chemical signals between organisms is considered the oldest form ... interactions between conspecifics, for example, the sexual attraction between ... social responses and to coordinate reproductive behavior in males ... the University of the Algarve in Faro, Portugal, and ...
Breaking Biology News(10 mins):Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Ready for mating at the right time 2Ready for mating at the right time 3
... host the first-ever Central Gulf of Mexico Hurricane Conference ... meeting will bring together 300-500 experts and officials from ... local public safety personnel, forecasters, university officials to ... 1 start of the 2010 Atlantic hurricane season. ...
... This release is available in German . ... last interglacial epoch, around 115,000 years ago, there were ... slow transition from the Eemian Interglacial to the Weichselian ... trends with possibly at least two warming events. This ...
... people worldwide. It is the most common form of age-related ... is no cure, and the available drugs only help to ... the characteristic changes in the brains of Alzheimer,s patients is ... for curing or at least slowing the disease lies in ...
Cached Biology News:2010 Central Gulf of Mexico Hurricane Conference, Baton Rouge, March 16-17 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2The sea squirt offers hope for Alzheimer's sufferers 2
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
... XL provides balance data collection and automation that ... integration with Microsoft Excel , Pre-configured library ... , New balances can be added and configured ... from multiple balances into one spreadsheet ...
...
... With increasing age, the autofluorescent ... of many cell types, including neurons. ... complicate the use of fluorescence microscopy ... of its broad excitation and emission ...
Biology Products: